X

CTS History

01Dec

Babesia

In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.

About the Author

Related

Disaster Reliability via Merged Information Systems

Disaster Reliability via Merged Information Systems

In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...

Read More >
Source plasma partners

Source plasma partners

By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...

Read More >

Operational Excellence

CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...

Read More >
CTS implements licensesd Zika test

CTS implements licensesd Zika test

CTS transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and ...

Read More >

Research Consortium

CTS Research Consortium was established to further CTS’s leadership in infectious disease research....

Read More >
CTS merges with the three Red Cross testing laboratories

CTS merges with the three Red Cross testing laboratories

CTS merges with the three Red Cross testing laboratories located in Charlotte, Portland and St. Loui...

Read More >